Európska únia -
fínčina -
EMA (European Medicines Agency)
evenity
ucb pharma s.a. - romosozumab - osteoporoosi - lääkkeet luusairauksien hoitoon - evenity on tarkoitettu vaikean osteoporoosin postmenopausaalisilla naisilla, joilla on suuri riski saada murtuma.
Európska únia -
fínčina -
EMA (European Medicines Agency)
neptra
bayer animal health gmbh - florfenikoliin, terbinafiini hydrokloridi, mometasone furoate - otologicals, kortikosteroidit ja antiinfectives in combination - koirat - hoitoon akuutti koiran ulkokorvatulehdus tai akuutisti pahentuneen toistuvan otitis aiheuttamia sekainfektioita ja herkät bakteerit herkkiä florfenikoliin (staphylococcus pseudintermedius) ja sienet herkkä terbinafiini (malassezia pachydermatis-hiivaa).
Fínsko -
fínčina -
Fimea (Suomen lääkevirasto)
paracetamol krka 500 mg tabletti
krka, d.d., novo mesto - paracetamol - tabletti - 500 mg - parasetamoli
Fínsko -
fínčina -
Fimea (Suomen lääkevirasto)
paracetamol krka 1000 mg tabletti
krka, d.d., novo mesto - paracetamol - tabletti - 1000 mg - parasetamoli
Európska únia -
fínčina -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - silmätautien - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Európska únia -
fínčina -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Európska únia -
fínčina -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
Fínsko -
fínčina -
Fimea (Suomen lääkevirasto)
gelofusine 40 mg/ml infuusioneste, liuos
b. braun melsungen ag - gelatin - infuusioneste, liuos - 40 mg/ml - gelatiini-polymeerit
Fínsko -
fínčina -
Fimea (Suomen lääkevirasto)
piperacillin/tazobactam pfizer 2 g / 0.25 g infuusiokuiva-aine, liuosta varten
pfizer pfe finland oy - piperacillinum natricum,tazobactamum natricum - infuusiokuiva-aine, liuosta varten - 2 g / 0.25 g - piperasilliini ja beetalaktamaasin estäjä
Fínsko -
fínčina -
Fimea (Suomen lääkevirasto)
piperacillin/tazobactam pfizer 4 g / 0.5 g infuusiokuiva-aine, liuosta varten
pfizer pfe finland oy - tazobactamum natricum,piperacillinum natricum - infuusiokuiva-aine, liuosta varten - 4 g / 0.5 g - piperasilliini ja beetalaktamaasin estäjä